Literature DB >> 9671864

Laparoscopic radical nephrectomy with morcellation for renal cell carcinoma: the Saskatoon experience.

P H Barrett1, D D Fentie, L A Taranger.   

Abstract

OBJECTIVES: To assess safety and effectiveness of laparoscopic radical nephrectomy with specimen entrapment and morcellation in patients with suspected renal cell carcinoma.
METHODS: We reviewed 72 patients with solid tumors who were offered an attempt at laparoscopic radical nephrectomy.
RESULTS: Of 72 patients approached laparoscopically, 6 were converted to open nephrectomy. In the remaining 66 patients with tumor size on computed tomography scan ranging from 1.0 to 9.0 cm (average 4.5 cm), the nephrectomy was completed laparoscopically and the specimen morcellated for extraction. Eight patients were clinical Stage T1N0M0, 60 were T2N0M0, 3 were T3N0M0, and 1 was T2N0M1. There was one unexplained death but complications otherwise were minimal. Operating time ranged from 1 hour 40 minutes to 4 hours 52 minutes (average 2 hours 55 minutes). The average length of stay was 4.4 days (range 3 to 7 days) for the laparoscopic group. The average specimen weight was 402.5 g (range 115 to 964). Review of histologic findings revealed renal cell carcinoma in 57 patients, benign tumors in 6, and no diagnosis in 3. Follow-up on the malignancies ranges from 1.5 to 58 months (average 21.4), with no port site recurrences and no known disease progression.
CONCLUSIONS: At an average follow-up of 21.4 months, laparoscopic radical nephrectomy with specimen entrapment and morcellation appears to be a safe and effective alternative to conventional open radical nephrectomy for renal malignancy.

Entities:  

Mesh:

Year:  1998        PMID: 9671864     DOI: 10.1016/s0090-4295(98)00159-9

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  12 in total

1.  Laparoscopic radical nephrectomy: morcellate or leave intact? Leave intact.

Authors:  Jihad H Kaouk; Inderbir S Gill
Journal:  Rev Urol       Date:  2002

2.  Laparoscopic versus open nephrectomy in 210 consecutive patients: outcomes, cost, and changes in practice patterns.

Authors:  K W Kercher; B T Heniford; B D Matthews; T I Smith; A E Lincourt; D H Hayes; L B Eskind; P B Irby; C M Teigland
Journal:  Surg Endosc       Date:  2003-10-23       Impact factor: 4.584

Review 3.  Laparoscopic nephrectomy for renal cell carcinoma.

Authors:  I Y Kim; P G Schulam
Journal:  Curr Urol Rep       Date:  2001-02       Impact factor: 2.862

Review 4.  Laparoscopic radical nephrectomy: retroperitoneal versus transperitoneal approach.

Authors:  Surena F Matin; Inderbir S Gill
Journal:  Curr Urol Rep       Date:  2002-04       Impact factor: 2.862

Review 5.  Laparoscopic approaches to urologic malignancies.

Authors:  Surena F Matin
Journal:  Curr Treat Options Oncol       Date:  2003-10

Review 6.  Taking the side of transperitoneal access for surgery in upper urinary tract.

Authors:  Mohamad E Allaf; Sam B Bhayani; Louis R Kavoussi
Journal:  Curr Urol Rep       Date:  2004-04       Impact factor: 2.862

Review 7.  Specimen processing during laparoscopic renal surgery: a review of techniques and technologies.

Authors:  Saleh Binsaleh
Journal:  Clinics (Sao Paulo)       Date:  2014       Impact factor: 2.365

Review 8.  Options on fibroid morcellation: a literature review.

Authors:  Hans Brölmann; Vasilios Tanos; Grigoris Grimbizis; Thomas Ind; Kevin Philips; Thierry van den Bosch; Samir Sawalhe; Lukas van den Haak; Frank-Willem Jansen; Johanna Pijnenborg; Florin-Andrei Taran; Sara Brucker; Arnaud Wattiez; Rudi Campo; Peter O'Donovan; Rudy Leon de Wilde
Journal:  Gynecol Surg       Date:  2015-02-07

Review 9.  Laparoscopic radical nephrectomy for advanced kidney cancer.

Authors:  Stephen E Pautler; McClellan M Walther
Journal:  Curr Urol Rep       Date:  2002-02       Impact factor: 2.862

Review 10.  Should laparoscopy be the standard approach used for radical nephrectomy?

Authors:  A J Portis; R V Clayman
Journal:  Curr Urol Rep       Date:  2001-04       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.